1 month Keros Therapeutics (NASDAQ:KROS) Earns Overweight Rating from Analysts at Cantor FitzgeraldMarketBeat
Cantor Fitzgerald initiated coverage on Keros Therapeutics in a research report on Thursday. They set an “overweight” rating for the company.
X